Trial: 202008047

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-
73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in
Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in
Participants With Advanced Non-Small Cell Lung Cancer

Phase

I

Principal Investigator

Waqar, Saiama

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov